posted on 2016-05-23, 00:00authored byMichael J. Genin, Isabel C. Gonzalez Valcarcel, William G. Holloway, Jason Lamar, Marian Mosior, Eric Hawkins, Thomas Estridge, Jeffrey Weidner, Thomas Seng, David Yurek, Lisa
A. Adams, Jennifer Weller, Vincent L. Reynolds, Joseph T. Brozinick
To develop novel
treatments for type 2 diabetes and dyslipidemia,
we pursued inhibitors of serine palmitoyl transferase (SPT). To this
end compounds 1 and 2 were developed as
potent SPT inhibitors in vitro. 1 and 2 reduce
plasma ceramides in rodents, have a slight trend toward enhanced insulin
sensitization in DIO mice, and reduce triglycerides and raise HDL
in cholesterol/cholic acid fed rats. Unfortunately these molecules
cause a gastric enteropathy after chronic dosing in rats.